



## King's Research Portal

DOI:

[10.1159/000448369](https://doi.org/10.1159/000448369)

*Document Version*

Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Møller, R. S., Larsen, L. H. G., Johannesen, K. M., Talvik, I., Talvik, T., Vaher, U., Miranda, M. J., Farooq, M., Nielsen, J. E. K., Svendsen, L. L., Kjølgaard, D. B., Linnet, K. M., Hao, Q., Uldall, P., Frangu, M., Tommerup, N., Baig, S. M., Abdullah, U., Born, A. P., ... Dahl, H. A. (2016). Gene Panel Testing in Epileptic Encephalopathies and Familial Epilepsies. *Molecular syndromology*, 7(4), 210-219. <https://doi.org/10.1159/000448369>

### Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### Take down policy

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

# Gene Panel Testing in Epileptic Encephalopathies and Familial Epilepsies

Rikke S. Møller, Line H.G. Larsen, [...], and Hans A. Dahl

## Abstract

In recent years, several genes have been causally associated with epilepsy. However, making a genetic diagnosis in a patient can still be difficult, since extensive phenotypic and genetic heterogeneity has been observed in many monogenic epilepsies. This study aimed to analyze the genetic basis of a wide spectrum of epilepsies with age of onset spanning from the neonatal period to adulthood. A gene panel targeting 46 epilepsy genes was used on a cohort of 216 patients consecutively referred for panel testing. The patients had a range of different epilepsies from benign neonatal seizures to epileptic encephalopathies (EEs). Potentially causative variants were evaluated by literature and database searches, submitted to bioinformatic prediction algorithms, and validated by Sanger sequencing. If possible, parents were included for segregation analysis. We identified a presumed disease-causing variant in 49 (23%) of the 216 patients. The variants were found in 19 different genes including *SCN1A*, *STXBPI*, *CDKL5*, *SCN2A*, *SCN8A*, *GABRA1*, *KCNA2*, and *STX1B*. Patients with neonatal-onset epilepsies had the highest rate of positive findings (57%). The overall yield for patients with EEs was 32%, compared to 17% among patients with generalized epilepsies and 16% in patients with focal or multifocal epilepsies. By the use of a gene panel consisting of 46 epilepsy genes, we were able to find a disease-causing genetic variation in 23% of the analyzed patients. The highest yield was found among patients with neonatal-onset epilepsies and EEs.

**Key Words:** Epileptic encephalopathies, Familial epilepsies, Gene panel testing, Seizures

During the last decade, great progress has been made in epilepsy genetics. This has primarily been technology driven due to the development of massive parallel sequencing. The extreme drop in sequencing costs has made it feasible to do whole-exome sequencing (WES) on family trios, which has led to the discovery of several novel epilepsy-related genes and elucidated new molecular pathways [for review, see [McTague et al., 2016](#)]. At the same time, it has been proposed by the International League Against Epilepsy Commission on terminology to replace the term ‘idiopathic’ with the term ‘genetic’, acknowledging the role of genetic factors in the large group of previously labeled idiopathic epilepsies [[Berg et al., 2010](#)].

The group of genetic epilepsies has a wide phenotypic spectrum, ranging from mild treatable seizure disorders in individuals with normal cognition to severe early-onset epileptic encephalopathies (EEs) associated with profound intellectual disability (ID). The genetic etiology of the different epilepsies is just as heterogeneous as the phenotypic spectrum, ranging from monogenic causes with little or no influence from modifiers or environmental factors to genetically complex forms involving multiple genes, modifiers and likely environmental factors [[Thomas and Berkovic, 2014](#)]. Extensive phenotypic and genetic heterogeneity has been observed in many monogenic epilepsies, meaning that genotype-phenotype correlations are not always straightforward. The same gene and even the same mutation can lead to broad phenotypic variations, and the same epilepsy syndrome can be caused by mutations in different genes [[Depienne et al., 2011](#); [Marini et al., 2011](#); [Carvill et al., 2014](#); [Goldberg-Stern et al., 2014](#); [Møller et al., 2015](#)]. This illustrates the insufficiency of the previous single gene test approach and the need for a multigene next-generation sequencing (NGS)-based strategy, either as full-genome sequencing, WES, or targeted gene panels.

Here, we report the results of screening by a gene panel containing 46 known epilepsy genes on a cohort of 216 patients with various forms of epilepsy, and we discuss the yields of such an approach from a diagnostic and therapeutic perspective.

## Patients and Methods

### Patients

The patients included in the study were probands referred with various forms of epilepsy from Denmark, Estonia, the UK, Argentina, and Pakistan, which were sent for genetic analysis over a period of time of 16 months from March 2014 to July 2015. The cohort consisted of 216 patients with a diverse range of EE phenotypes or milder familial epilepsies. The age at referral was between 2 weeks and 74 years of age. Forty-nine (23%) of the patients were over 18 years of age. Seizure and medical histories provided by the referring physicians were evaluated, and, if possible, epilepsy syndromes were classified according to the International League Against Epilepsy [[Berg et al., 2010](#)]. The majority of the patients (n = 112; 52%) had different EEs, including Ohtahara syndrome, West syndrome, malignant migrating partial seizures of infancy, and unspecified EEs with seizure onset within the first years of life. Forty-four (20%) of the patients had multifocal or focal epilepsies including benign familial neonatal or infantile seizures (BFIS) and autosomal dominant nocturnal frontal lobe epilepsy. Twenty-three (11%) patients had generalized epilepsies, including genetic generalized epilepsy, generalized epilepsy with febrile seizures+ (GEFS+), myoclonic atonic epilepsy, or early-onset absence epilepsy. The remaining patients had unclassified epilepsies with or without ID. One patient had only recurrent long-lasting febrile seizures (FS+) and one patient turned out to have benign myoclonus of infancy instead of epilepsy. Detailed clinical information was not available for 19 patients. Less than 10% of the patients had previously undergone negative mutation screening for selected epilepsy genes, e.g., *SCN1A* and *STXBPI*.

## The Gene Panel

To identify presumed disease-causing variants, we performed targeted NGS of 46 epilepsy genes. The criteria for including a gene on the panel were that it should have been reported more than once in patients with monogenic epilepsies. The selection of genes was made in January 2014, meaning that some genes discovered in the past 2 years were not included on this panel - exceptions are some unpublished gene discoveries the authors were aware of when the panel was developed, e.g., *KCNA2*, *STX1B*, *GABRA1*, *DNM1*, and *HCN1* [Carvill et al., 2014; EuroEPINOMICS-RES Consortium et al., 2014; Nava et al., 2014; Schubert et al., 2014; Syrbe et al., 2015]. The genes included on the present panel are: *ALDH7A1*, *ALG13*, *ARHGE1*, *CACNA1A*, *CDKL5*, *CHD2*, *CPA6*, *DEPDC5*, *DNM1*, *GABRA1*, *GABBR1*, *GABBR2*, *GABRB3*, *GABRD*, *GABRG2*, *GNAO1*, *GRIN1*, *GRIN2A*, *GRIN2B*, *HCN1*, *HDAC4*, *HNRNPU*, *IQSEQ2*, *KCNA2*, *KCNQ2*, *KCNQ3*, *KCNT1*, *KCTD7*, *LGII*, *MBD5*, *PDCH19*, *PLCB1*, *PNPO*, *PRRT2*, *SCN1A*, *SCN1B*, *SCN2A*, *SCN8A*, *SLC25A22*, *SLC2A1*, *SLC35A3*, *SPTAN1*, *STX1B*, *STXBPI*, *SYNGAP1*, and *TBC1D24*.

## Sample Preparation

Genomic DNA was extracted from full blood using standard methods. Targeted NGS libraries were prepared from 15 ng of template DNA using the Ion AmpliSeq library 2.0 kit and custom primers following the manufacturer's instructions (Life Technologies). Sequencing adaptors with index sequences (barcodes) that enable sample multiplexing were ligated to the amplicons using the Ion Xpress barcode adaptor kit (Life Technologies). The library DNA was clonally amplified onto the Ion Spheres Particles (ISPs) by emulsion PCR using an Ion OneTouch 2 system and the Ion PGM Template OT2 200 kit (Life Technologies). ISPs were sequenced on an Ion PGM sequencer using an Ion 314 or Ion 316 chip and the Ion PGM 200 Sequencing kit as per the manufacturer's instructions (Life Technologies).

## Bioinformatics

Sequences were mapped to hg19 in the Torrent suite software (Life Technologies) and variant calling was achieved in the Strand NGS software (Avadis) with a minimum of 20-fold read depth. Common SNPs with an allele frequency  $\geq 2\%$  and SNPs observed in more than 2 samples for each analyzed sample batch were filtered out. Genetic nonsynonymous/splice site variants were evaluated through database searches such as dbSNP, Exome Variant Server, the Exome Aggregation Consortium database (ExAC), and HGMD Professional. Missense variants were also submitted to prediction softwares such as SIFT and PolyPhen-2, while splice site variants were evaluated by NNSplice and Splicesite finder. Variants analyzed under a dominant inheritance model that were observed more than 10 times in ExAC were considered too common and discarded. Potentially pathogenic variants were validated through conventional Sanger sequencing, and, if possible, parents were included for segregation analysis.

## Criteria for Pathogenicity of Rare Variants

For possibly damaging variants where segregation analysis could be performed, we required the variant to meet one of the following criteria to constitute a possible pathogenic variant: it arose de novo, segregated with the disorder, was inherited from a parent with somatic mosaicism, was inherited from an unaffected parent but previously reported in other families with the same phenotype and incomplete penetrance, or adhered to a recessive X-linked or parent-of-origin mode of inheritance. Paternity testing was not performed.

## Results

The overall target coverage of the 46 genes was 95-97%; hence, 3-5% of the regions were not analyzed, and some variations may be missed for this reason. The regions missed were more or less identical across the different samples, i.e., regions difficult to amplify due to high GC content, repeat elements, or regions with homology in other parts of the genome. We identified presumed disease-causing variations in 49 of 216 patients (table 1), corresponding to a diagnostic yield of 23%. The variations constituted both known and novel variants in 19 different genes, and all were predicted damaging by one or more softwares.

Sample ID	Phenotype	Gene	RefSeq	Protein
011371	MMSE	CHRNA1	c.300G>C	p.G100V

Table 1

Presumed disease-causing mutations

Twenty-one patients had neonatal-onset epilepsies, e.g., benign familial neonatal seizures or neonatal-onset EEs, and presumed pathogenic variants were found in 12 of these cases corresponding to a yield of 57%. In comparison, only 4/29 (14%) patients with seizure onset between 2 and 9 years of age had a positive finding, and no disease-causing variants were found among 9 patients with seizure onset between 10 and 28 years. The epilepsy phenotypes in the 2 latter groups included myoclonic atonic epilepsy, genetic generalized epilepsy (childhood absence epilepsy, juvenile absence

epilepsy, and juvenile myoclonic epilepsy), and focal or multifocal epilepsies. The remaining 138 patients for whom data on seizure onset was available had onset between 2 months and 2 years and a presumed pathogenic variant was found in 36 (26%) of them.

Thirty-six of the 49 presumed pathogenic variants were found among 112 patients with EEs (yield: 32%). In comparison, 7 variants were detected in 44 patients with focal or multifocal epilepsies including benign familial neonatal seizures, BFIS, and autosomal dominant nocturnal frontal lobe epilepsy (yield: 16%), and 4 variants were detected among 23 patients with generalized epilepsies, e.g., GEFS+ (yield: 17%). The remaining 2 presumed disease-causing variants were found in patients with FS+ or unclassified epilepsy and ID, respectively. Six variants had been seen between 5 and 5 times in ExAC. Four of these were found in patients with relatively mild phenotypes: FS+ (*SCN1A*), GEFS+ (*SCN1A*) or focal epilepsy (*CP2*: and *KCNT1*), while another was one of a pair of compound heterozygous variants in a recessive gene (*PNPO*).

Segregation analysis was performed in 33 of the 49 cases; 29 of the variants occurred de novo, 2 were homozygous or compound heterozygous (*PNPO*, and *PRRT2*), 3 were inherited from an affected parent (*KCNT1*, *GABRA1*, and *KCNQ2*), and 1 variant (*SLC2A1*) was inherited from an unaffected parent. This particular *SLC2A1* variant has previously been reported in a family with paroxysmal exertion-induced dyskinesias, epilepsy, mild ID, impulsivity, and incomplete penetrance [Weber et al., 2008]. Parental DNA was not available for the remaining 16 presumed disease-causing variants. However, the majority of these 16 variants were either frameshift, nonsense, or splice site variants observed in known EE genes, e.g., *SCN1A*, *STXBPI*, and *CDKL5* (7/16 variants) or missense variants that have previously been reported in patients affected by the same epilepsy syndrome as observed in the proband (5/16 variants).

We identified multiple patients with disease-causing variants in the most common epilepsy genes *SCN1A* (n = 12), *SCN2A* (n = 6), *STXBPI* (n = 4), *CDKL5* (n = 4), *SLC2A1* (n = 3), *SCN8A* (n = 3), and *KCNQ2* (n = 3) accounting for 71% (35/49) of all mutation-positive individuals in our cohort. Furthermore, we found pathogenic variants in the relatively undescribed epilepsy genes *GABRA1* and *GABRB3* in 2 individuals each. 8 of the 49 presumed disease-causing variants have already been published in other studies [Møller et al., 2015; Talvik et al., 2015; Epi4K Consortium, 2016; Stamberger et al., 2016].

Three of the 12 *SCN1A* variants were found in patients with FS+ or GEFS+ syndrome, whereas the additional 9 *SCN1A* variants were associated with Dravet syndrome. Seven out of the 9 Dravet-associated alterations were found in adults between 20 and 53 years of age previously diagnosed with an unspecified EE and ID. All 7 individuals were retrospectively diagnosed with Dravet syndrome. Five of them were being treated with lamotrigine and/or carbamazepine, which were tapered off after the *SCN1A* variant was found. The changes in medication led to improved alertness and gait in 2 patients (p.Gly1757Arg, p.Glu1032\*) and worsening of the seizure frequency or behavior in 2 patients (p.Gly177Glu, p.Leu942Val), whereas the condition was unchanged in the last patient.

Three de novo variants in *SCN8A* were identified in the present cohort, 2 missense variants (p.Thr239Ser, p.Ile1532Phe), and 1 nonsense mutation (p.Arg1820\*). The 2 missense variants were found in 2 girls with severe early-onset EE, hypotonia, dyskinetic movements, and profound ID without any spoken language, a phenotype identical to previously published patients with *SCN8A* encephalopathy [Larsen et al., 2015]. Both girls were resistant to a variety of antiepileptic drugs, including valproate and levetiracetam. However, one of them (p.Ile1532Phe) was treated with oxcarbazepine, a sodium channel blocker (SCB), which gave a significant seizure reduction. Interestingly, we found, to the best of our knowledge, the first *SCN8A* nonsense mutation in a 5-year-old boy with mild ID and onset of mild myoclonic seizures at the age of 3 months. He initially had a few generalized tonic-clonic seizures (GTCS), but at present, only mild myoclonic seizures in the fingers and hands remain. The boy's EEG has shown epileptiform changes compatible with multifocal epilepsy. He has been treated with lamotrigine with moderate response.

Only 2 homozygous or compound heterozygous variants (*PNPO*, *PRRT2*) were identified. A homozygous variant in *PRRT2* (p.Pro279Leu) was found in a 16-month-old boy born to healthy unrelated Danish parents. There was no history of epilepsy in the family. He had onset of clusters of focal and generalized seizures at 3 months of age. His epilepsy was classified as benign infantile epilepsy, and seizure control was achieved with levetiracetam and valproate. Initial EEG recordings showed a focus of sharp waves in the right centro-parietal region, which normalized at 6 months. At the age of 6 months, he developed a movement disorder with head titubations, which improved after change from valproate to oxcarbazepine. He is currently developing but has mild delay in motor milestones.

In addition, to the 49 above-mentioned variants, we identified 7 (3%) variants of unknown significance (VUS; table 2). Segregation analysis was only performed for 2 of these variants (*STX1B* and *ALG13*). The *STX1B* alteration was found in a girl with prolonged febrile seizures as well as afebrile GTCS and inherited from her unaffected father and grandfather. Mutations in *STX1B* encoding syntaxin-1B have recently been found in sporadic cases and families with fever-associated epilepsy syndromes [Schubert et al., 2014]. Incomplete penetrance has been reported [Schubert et al., 2014], which makes the finding in this family difficult to interpret. The *ALG13* variant was observed in a male patient with Lennox-Gastaut syndrome and shown to be inherited from the unaffected mother and grandmother. It was predicted damaging by different softwares and not present in ExAC. However, unfortunately no additional male family members were available for testing, and we were therefore unable to classify pathogenicity of this variant.

Sample ID	Phenotype	Gene	cDNA	Protein	p-value
EE0858225	EE	ABCC11	c.10401G>T		p.D3647Gfs
EE12109	West syndrome	ABHD10	c.1304G>C		Q4348fs
EP152	epilepsy, ID	ABHD10	c.2078A>C		p.L696Afs
3040	ID	ABHD10	c.2078A>C		p.L696Afs
SC11044	IDS	ATP5B1	c.4059G>A		Q1357fs

Table 2

Variants of unknown significance

## Discussion

In the present study, we screened a cohort of 216 patients with various forms of epilepsies of suspected genetic cause. A presumed disease-causing variant was found in 23%, and a VUS was found in additional 3%. Targeted epilepsy gene panels are increasingly being used in research, and diagnostic laboratories and several studies using gene panels consisting of 35–265 genes have been published with diagnostic yields ranging between 10 and 48.5% [Lemke et al., 2012; Carvill et al., 2013a; Kodera et al., 2013; Wang et al., 2014; Della Mina et al., 2015; Mercimek-Mahmutoglu et al., 2015]. In these studies, there was a clear tendency towards higher positive rates in patients with early-onset epilepsies as well as in cases with severe phenotypes, and as expected, the observed de novo rate was high [Epi4K Consortium et al., 2013]. We identified a pathogenic variant in 57% of the patients with neonatal-onset epilepsies compared to only 14% of patients with onset between 2 and 9 years of age. No disease-causing variants were found among 9 patients with genetic generalized epilepsy, focal or unclassified epilepsy and onset between age 10 and 28 years. The overall diagnostic yield for patients with EEs was 32%, compared to 16% in patients with focal or multifocal epilepsy. These diagnostic yields are similar to published studies on other targeted NGS panels [Lemke et al., 2012; Carvill et al., 2013a; Kodera et al., 2013; Wang et al., 2014; Della Mina et al., 2015; Mercimek-Mahmutoglu et al., 2015].

Presumed disease-causing *SCN1A* variants were found in 7 adults who were retrospectively diagnosed with Dravet syndrome. Dravet syndrome is caused by *SCN1A* mutations that are usually believed to result in loss of function, leading to lack of sodium channel function in inhibitory interneurons. SCBs are therefore usually contraindicated in *SCN1A*-related Dravet syndrome. Five of the 7 identified adults were tapered off SCB based on their genetic profile. Two of them clearly benefited from this change in treatment with improvement in alertness and gait. However, surprisingly 2 of them had worsening of seizure frequency or behavior after tapering off lamotrigine. One patient experienced less GTCS but more focal seizures and changes in behavior (irritability), whereas the other patient had an increased frequency of GTCS. The 2 patients did not have further changes in their medications; thus, no additional drugs were added. Both patients had an *SCN1A* missense variant p.Gly177Glu and p.Leu942Val, which raises the question whether Dravet syndrome also can be caused by gain-of-function mutations as seen in EEs caused by other sodium channel genes, e.g., *SCN2A* and *SCN8A* [Kearney et al., 2001; Veeramah et al., 2012]. In the 2 patients harboring an *SCN8A* missense variant, we found, as previously reported [Wagnon and Meisler, 2015; Boerma et al., 2016; Möller and Johannesen, 2016], a good response to the SCB oxcarbazepine and a poor response to levetiracetam [Wagnon and Meisler, 2015]. The patient with the *SCN8A* nonsense mutation has been treated with lamotrigine, despite the fact that this variant is likely to cause a LOF loss of function of the channel. These findings indicate that a gene panel approach can provide data that in some cases can translate positively into clinical practice, whereas in other instances, they demand further preclinical investigations.

We also found a de novo variant in *GRIN2A* (p.Asn614Ser), encoding the NMDA receptor subunit GluN2A in a 2-year-old boy with severe ID, severe hypotonia, ataxia, and onset of intractable focal epilepsy at the age of 3 months. Mutations in *GRIN2A* have been found in a significant subset of patients with epilepsy-aphasia syndromes, comprising a phenotypic spectrum from atypical benign partial epilepsy to EEs with continuous spikes and waves during slow-wave sleep and Landau-Kleffner syndrome [Carvill et al., 2013b; Lemke et al., 2013; Lesca et al., 2013]. Furthermore, a few cases with severe early-onset EEs and severe ID as seen in the present case have been reported [Pierson et al., 2014]. The identified variant p.Asn614Ser is positioned directly at the tip of the re-entrant pore loop of GluN2A. Variants of this domain have been shown to result in a significant loss of the Mg<sup>2+</sup> block resulting in a marked gain of channel function and severe neurodevelopmental delay [Endele et al., 2010]. Pierson et al. [2014] recently reported that treatment with an NMDA receptor blocker, memantine, in a patient with intractable epilepsy and ID due to a *GRIN2A* gain-of-function mutation resulted in marked reduction of seizure frequency. However, the efficacy of memantine in patients with *GRIN2A* gain-of-function mutations remains to be confirmed in clinical trials.

Only 2 recessive variants were found in the present cohort (table 1). One of them was a homozygous *PRRT2* variant found in a 16-month-old boy with BFIS, movement disorder, and mild gross motor delay. Heterozygous *PRRT2* mutations have been associated with a spectrum of conditions including BFIS, infantile convulsions and choreoathetosis and paroxysmal kinesigenic dyskinesia. ID has been reported in less than 1% of patients with heterozygous *PRRT2* mutations, whereas >60% of the patients with homozygous or compound heterozygous *PRRT2* mutations present with ID or learning difficulties [for review, see Ebrahimi-Fakhari et al., 2015]. The present patient is developing but has mild gross motor delay, and due to his young age, it is not possible to evaluate his cognitive outcome.

A selected gene panel approach can be a comparable alternative to WES analysis. The benefit of a gene panel compared to WES is the targeted approach, meaning that only phenotypically relevant genes are included, which reduces or even eliminates incidental findings. In this study, we also observed a relatively low fraction of VUS (3%) compared to some recent WES studies where the observed VUS fraction was ~10% [Yang et al.,

2014; Helbig et al., 2016]. Furthermore, the limited number of genes allows higher sequencing read depth at lower costs than WES and therefore better analysis quality. The drawback is that the panels have a predefined number of genes, and any later novel gene discoveries demand a whole new setup from data generation to analysis. The present panel, as most of the previously published panels, has a slightly lower diagnostic yield compared to a WES diagnostic, in which a genetic diagnosis can be found in 33-58% depending on the epilepsy phenotype [Helbig et al., 2016]. Here, we show 23% overall positive findings and 57% for patients with neonatal-onset epilepsies, indicating that for this particular subgroup not much is gained by an exome-wide approach. Compared to a smaller panel, a large panel including hundreds of genes is not always more informative and often adds more confusion with its higher VUS rate and inclusion of genes which are not or only marginally associated with the phenotype. Furthermore, there is an ethical and consent issue in testing well-defined patients with a large panel containing genes not relevant for the phenotype under study because the potential need to counsel for incidental findings. The challenging task for the molecular geneticist is therefore to design a panel with relevant genes. However, both the designer of the panels and the referring clinician have to be aware of the phenotypic target of the panel reflected in the selection of genes.

## Statement of Ethics

The study has been approved by the local ethical committees.

## Disclosure Statement

The authors have no conflicts of interest to declare.

## Acknowledgments

The Lundbeck Foundation (2013-14290), the UCPH Programme for Interdisciplinary Research (Global Genes, Local Concerns), and The Danish Council for Independent Research - Medical Sciences (4183-00482B) are kindly acknowledged.

## Article information

Mol Syndromol. 2016 Sep; 7(4): 210–219.

Published online 2016 Aug 20. doi: [10.1159/000448369](https://doi.org/10.1159/000448369)

PMCID: PMC5073625

PMID: [27781031](https://pubmed.ncbi.nlm.nih.gov/27781031/)

Rikke S. Møller,<sup>a,c,\*</sup> Line H.G. Larsen,<sup>d</sup> Katrine M. Johannesen,<sup>a,c</sup> Inga Talvik,<sup>m,n</sup> Tiina Talvik,<sup>n,o</sup> Ulvi Vaher,<sup>n,o</sup> Maria J. Miranda,<sup>a</sup> Muhammad Farooq,<sup>l,p</sup> Jens E.K. Nielsen,<sup>f</sup> Lene Lavard Svendsen,<sup>g</sup> Ditte B. Kjelgaard,<sup>a</sup> Karen M. Linnet,<sup>h</sup> Qin Hao,<sup>d</sup> Peter Uldall,<sup>a</sup> Mimoza Frangu,<sup>j</sup> Niels Tommerup,<sup>i</sup> Shahid M. Baig,<sup>p</sup> Uzma Abdullah,<sup>l,p</sup> Alfred P. Born,<sup>k</sup> Pia Gellert,<sup>a</sup> Marina Nikanorova,<sup>a,c</sup> Kern Olofsson,<sup>a</sup> Birgit Jepsen,<sup>a</sup> Dragan Marjanovic,<sup>a</sup> Lana I.K. Al-Zehhawi,<sup>i</sup> Sofia J. Peñalva,<sup>q</sup> Bente Krag-Olsen,<sup>h</sup> Klaus Brusgaard,<sup>d</sup> Helle Hjalgrim,<sup>a,c</sup> Guido Rubboli,<sup>b</sup> Deb K. Pal,<sup>r</sup> and Hans A. Dahl<sup>d</sup>

<sup>a</sup>Danish Epilepsy Centre, University of Southern Denmark, Denmark

<sup>b</sup>Danish Epilepsy Centre, Filadelfia, Dianalund, Denmark

<sup>c</sup>Institute for Regional Health Services, University of Southern Denmark, Denmark

<sup>d</sup>Amplexa Genetics, Odense, Denmark

<sup>e</sup>Department of Pediatrics, Pediatric Neurology, Herlev University Hospital, Copenhagen University, Herlev, Denmark

<sup>f</sup>Department of Clinical Medicine, Section of Gynaecology, Obstetrics and Paediatrics, Roskilde Hospital, Roskilde, Denmark

<sup>g</sup>Department of Pediatrics, Hvidovre Hospital, Hvidovre, Denmark

<sup>h</sup>Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark

<sup>i</sup>Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark

<sup>j</sup>Department of Pediatrics, Holbæk Hospital, Holbæk, Denmark

<sup>k</sup>Department of Paediatrics, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

<sup>l</sup>Department of Cellular and Molecular Medicine, Wilhelm Johannsen Centre for Functional Genome Research, University of Copenhagen, Copenhagen, Denmark

<sup>m</sup>Tallinn Children's Hospital, Tallinn, Estonia

<sup>n</sup>Tartu University Hospital, Children's Clinic, Tartu, Estonia

<sup>o</sup>Department of Paediatrics, University of Tartu, Tartu, Estonia

<sup>p</sup>Human Molecular Genetics Laboratory, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE)-PIEAS, Faisalabad, Pakistan

<sup>q</sup>CEMIC, Department of Genetics, Buenos Aires, Argentina

<sup>r</sup>Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

\*Rikke Steensbjerre Møller, Danish Epilepsy Centre, Research, Kolonivej 1, DK-4293 Dianalund (Denmark), E-Mail [rimo@filadelfia.dk](mailto:rimo@filadelfia.dk)



## References

1. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. *Epilepsia*. 2010;51:676–685. [PubMed] [Google Scholar]
2. Berkovic SF, Heron SE, Giordano L, Marini C, Guerrini R, et al. Benign familial neonatal-infantile seizures: characterization of a new sodium channelopathy. *Ann Neurol*. 2004;55:550–557. [PubMed] [Google Scholar]
3. Boerma RS, Braun KP, van de Broek MP, van Berkestijn FM, Swinkels ME, et al. Remarkable phenytoin sensitivity in 4 children with *SCN8A*-related epilepsy: a molecular neuropharmacological approach. *Neurotherapeutics*. 2016;13:192–197. [PMC free article] [PubMed] [Google Scholar]
4. Carvill GL, Heavin SB, Yendle SC, McMahon JM, O'Roak BJ, et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in *CHD2* and *SYNGAP1*. *Nat Genet*. 2013a;45:825–830. [PMC free article] [PubMed] [Google Scholar]
5. Carvill GL, Regan BM, Yendle SC, O'Roak BJ, Lozovaya N, et al. *GRIN2A* mutations cause epilepsy-aphasia spectrum disorders. *Nat Genet*. 2013b;45:1073–1076. [PMC free article] [PubMed] [Google Scholar]
6. Carvill GL, Weckhuysen S, McMahon JM, Hartmann C, Möller RS, et al. *GABRA1* and *STXBP1*: novel genetic causes of Dravet syndrome. *Neurology*. 2014;82:1245–1253. [PMC free article] [PubMed] [Google Scholar]
7. Cherepanova NS, Leslie E, Ferguson PJ, Bamshad MJ, Bassuk AG. Presence of epilepsy-associated variants in large exome databases. *J Neurogenet*. 2013;27:1–4. [PMC free article] [PubMed] [Google Scholar]
8. Della Mina E, Ciccone R, Brustia F, Bayindir B, Limongelli I, et al. Improving molecular diagnosis in epilepsy by a dedicated high-throughput sequencing platform. *Eur J Hum Genet*. 2015;23:354–362. [PMC free article] [PubMed] [Google Scholar]
9. Deng D, Xu C, Sun P, Wu J, Yan C, et al. Crystal structure of the human glucose transporter GLUT1. *Nature*. 2014;510:121–125. [PubMed] [Google Scholar]
10. Depienne C, Trouillard O, Bouteiller D, Gourfinkel-An I, Poirier K, et al. Mutations and deletions in *PCDH19* account for various familial or isolated epilepsies in females. *Hum Mutat*. 2011;32:E1959–E1975. [PMC free article] [PubMed] [Google Scholar]
11. Ebrahimi-Fakhari D, Saffari A, Westenberger A, Klein C. The evolving spectrum of *PRRT2*-associated paroxysmal diseases. *Brain*. 2015;138:3476–3495. [PubMed] [Google Scholar]
12. Ende S, Rosenberger G, Geider K, Popp B, Tamer C, et al. Mutations in *GRIN2A* and *GRIN2B* encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. *Nat Genet*. 2010;42:1021–1026. [PubMed] [Google Scholar]
13. Epi4K Consortium. De novo mutations in *SLC1A2* and *CACNA1A* are important causes of epileptic encephalopathies. *Am J Hum Genet*. 2016;99:287–298. [PMC free article] [PubMed] [Google Scholar]
14. Epi4K Consortium; Epilepsy Phenome/Genome Project. Allen AS, Berkovic SF, Cossette P, et al. De novo mutations in epileptic encephalopathies. *Nature*. 2013;501:217–221. [PMC free article] [PubMed] [Google Scholar]
15. EuroEPINOMICS-RES Consortium; Epilepsy Phenome/Genome Project; Epi4K Consortium De novo mutations in synaptic transmission genes including *DNM1* cause epileptic encephalopathies. *Am J Hum Genet*. 2014;95:360–370. [PMC free article] [PubMed] [Google Scholar]
16. Fukuma G, Oguni H, Shirasaka Y, Watanabe K, Miyajima T, et al. Mutations of neuronal voltage-gated Na<sup>+</sup> channel  $\alpha 1$  subunit gene *SCN1A* in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB) Epilepsia. 2004;45:140–148. [PubMed] [Google Scholar]
17. Goldberg-Stern H, Aharoni S, Afawi Z, Bennett O, Appenzeller S, et al. Broad phenotypic heterogeneity due to a novel *SCN1A* mutation in a family with genetic epilepsy with febrile seizures plus. *J Child Neurol*. 2014;29:221–226. [PubMed] [Google Scholar]
18. Goyal M, Fequiere PR, McGrath TM, Hyland K. Seizures with decreased levels of pyridoxal phosphate in cerebrospinal fluid. *Pediatr Neurol*. 2013;48:227–231. [PubMed] [Google Scholar]

19. Harkin LA, McMahon JM, Iona X, Dibbens L, Pelekanos JT, et al. The spectrum of *SCN1A*-related infantile epileptic encephalopathies. *Brain*. 2007;130:843–852. [PubMed] [Google Scholar]
20. Helbig KL, Farwell Hagman KD, Shinde DN, Mroske C, Powis Z, et al. Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy. *Genet Med*. 2016 Epub ahead of print. [PubMed] [Google Scholar]
21. Heron SE, Smith KR, Bahlo M, Nobili L, Kahana E, et al. Missense mutations in the sodium-gated potassium channel gene *KCNT1* cause severe autosomal dominant nocturnal frontal lobe epilepsy. *Nat Genet*. 2012;44:1188–1190. [PubMed] [Google Scholar]
22. Hoffman-Zacharska D, Szczepanik E, Terczynska I, Goszczanska-Ciuchta A, Zalewska-Miskurka Z, et al. From focal epilepsy to Dravet syndrome - heterogeneity of the phenotype due to *SCN1A* mutations of the p.Arg1596 amino acid residue in the Nav1.1 subunit. *Neurol Neurochir Pol*. 2015;49:258–266. [PubMed] [Google Scholar]
23. Howell KB, McMahon JM, Carvill GL, Tambunan D, Mackay MT, et al. *SCN2A* encephalopathy: a major cause of epilepsy of infancy with migrating focal seizures. *Neurology*. 2015;85:958–966. [PMC free article] [PubMed] [Google Scholar]
24. Ishii A, Fukuma G, Uehara A, Miyajima T, Makita Y, et al. A de novo *KCNQ2* mutation detected in non-familial benign neonatal convulsions. *Brain Dev*. 2009;31:27–33. [PubMed] [Google Scholar]
25. Kearney JA, Plummer NW, Smith MR, Kapur J, Cummins TR, et al. A gain-of-function mutation in the sodium channel gene *Scn2a* results in seizures and behavioral abnormalities. *Neuroscience*. 2001;102:307–317. [PubMed] [Google Scholar]
26. Kim GE, Kronengold J, Barcia G, Quraishi IH, Martin HC, et al. Human slack potassium channel mutations increase positive cooperativity between individual channels. *Cell Rep*. 2014a;9:1661–1672. [PMC free article] [PubMed] [Google Scholar]
27. Kim YO, Bellows S, McMahon JM, Iona X, Damiano J, et al. Atypical multifocal Dravet syndrome lacks generalized seizures and may show later cognitive decline. *Dev Med Child Neurol*. 2014b;56:85–90. [PubMed] [Google Scholar]
28. Kadera H, Kato M, Nord AS, Walsh T, Lee M, et al. Targeted capture and sequencing for detection of mutations causing early onset epileptic encephalopathy. *Epilepsia*. 2013;54:1262–1269. [PubMed] [Google Scholar]
29. Larsen J, Carvill GL, Gardella E, Kluger G, Schmiedel G, et al. The phenotypic spectrum of *SCN8A* encephalopathy. *Neurology*. 2015;84:480–489. [PMC free article] [PubMed] [Google Scholar]
30. Lemke JR, Riesch E, Scheurenbrand T, Schubach M, Wilhelm C, et al. Targeted next generation sequencing as a diagnostic tool in epileptic disorders. *Epilepsia*. 2012;53:1387–1398. [PubMed] [Google Scholar]
31. Lemke JR, Lal D, Reinthaler EM, Steiner I, Nothnagel M, et al. Mutations in *GRIN2A* cause idiopathic focal epilepsy with rolandic spikes. *Nat Genet*. 2013;45:1067–1072. [PubMed] [Google Scholar]
32. Lesca G, Rudolf G, Bruneau N, Lozovaya N, Labalme A, et al. *GRIN2A* mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. *Nat Genet*. 2013;45:1061–1066. [PubMed] [Google Scholar]
33. Liao Y, Anttonen AK, Liukkonen E, Gaily E, Maljevic S, et al. *SCN2A* mutation associated with neonatal epilepsy, late-onset episodic ataxia, myoclonus, and pain. *Neurology*. 2010a;75:1454–1458. [PubMed] [Google Scholar]
34. Liao Y, Deprez L, Maljevic S, Pitsch J, Claes L, et al. Molecular correlates of age-dependent seizures in an inherited neonatal-infantile epilepsy. *Brain*. 2010b;133:1403–1414. [PubMed] [Google Scholar]
35. Mancardi MM, Striano P, Gennaro E, Madia F, Paravidino R, et al. Familial occurrence of febrile seizures and epilepsy in severe myoclonic epilepsy of infancy (SMEI) patients with *SCN1A* mutations. *Epilepsia*. 2006;47:1629–1635. [PubMed] [Google Scholar]
36. Marini C, Scheffer IE, Nabbout R, Suls A, De Jonghe P, et al. The genetics of Dravet syndrome. *Epilepsia*. 2011;52:24–29. [PubMed] [Google Scholar]
37. McTague A, Howell KB, Cross JH, Kurian MA, Scheffer IE. The genetic landscape of the epileptic encephalopathies of infancy and childhood. *Lancet Neurol*. 2016;15:304–316. [PubMed] [Google Scholar]
38. Mercimek-Mahmutoglu S, Patel J, Cordeiro D, Hewson S, Callen D, et al. Diagnostic yield of genetic testing in epileptic encephalopathy in childhood. *Epilepsia*. 2015;56:707–716. [PubMed] [Google Scholar]
39. Milligan CJ, Li M, Gazina EV, Heron SE, Nair U, et al. *KCNT1* gain of function in 2 epilepsy phenotypes is reversed by quinidine. *Ann Neurol*. 2014;75:581–590. [PMC free article] [PubMed] [Google Scholar]



40. Mills PB, Camuzeaux SS, Footitt EJ, Mills KA, Gissen P, et al. Epilepsy due to *PNPO* mutations: genotype, environment and treatment affect presentation and outcome. *Brain*. 2014;137:1350–1360. [PMC free article] [PubMed] [Google Scholar]
41. Mirzaa GM, Paciorkowski AR, Marsh ED, Berry-Kravis EM, Medne L, et al. *CDKL5* and *ARX* mutations in males with early-onset epilepsy. *Pediatr Neurol*. 2013;48:367–377. [PMC free article] [PubMed] [Google Scholar]
42. Misra SN, Kahlig KM, George AL., Jr Impaired NaV1.2 function and reduced cell surface expression in benign familial neonatal-infantile seizures. *Epilepsia*. 2008;49:1535–1545. [PMC free article] [PubMed] [Google Scholar]
43. Møller RS, Johannesen KM. Precision medicine: *SCN8A* encephalopathy treated with sodium channel blockers. *Neurotherapeutics*. 2016;13:190–191. [PMC free article] [PubMed] [Google Scholar]
44. Møller RS, Heron SE, Larsen LH, Lim CX, Ricos MG, et al. Mutations in *KCNT1* cause a spectrum of focal epilepsies. *Epilepsia*. 2015;56:e114–120. [PMC free article] [PubMed] [Google Scholar]
45. Nabbout R, Gennaro E, Dalla Bernardina B, Dulac O, Madia F, et al. Spectrum of *SCN1A* mutations in severe myoclonic epilepsy of infancy. *Neurology*. 2003;60:1961–1967. [PubMed] [Google Scholar]
46. Nava C, Dalle C, Rastetter A, Striano P, de Kovel CG, et al. De novo mutations in *HCN1* cause early infantile epileptic encephalopathy. *Nat Genet*. 2014;46:640–645. [PubMed] [Google Scholar]
47. Petrelli C, Passamonti C, Cesaroni E, Mei D, Guerrini R, et al. Early clinical features in Dravet syndrome patients with and without *SCN1A* mutations. *Epilepsy Res*. 2012;99:21–27. [PubMed] [Google Scholar]
48. Pierson TM, Yuan H, Marsh ED, Fuentes-Fajardo K, Adams DR, et al. *GRIN2A* mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. *Ann Clin Transl Neurol*. 2014;1:190–198. [PMC free article] [PubMed] [Google Scholar]
49. Rocca FE, De Marco EV, Annesi F, Civitelli D, Provenzano G, et al. Novel human pathological mutations. Gene symbol: *SCN1A*. Disease: myoclonic epilepsy of infancy. *Hum Genet*. 2010;127:463. [PubMed] [Google Scholar]
50. Schmitt B, Baumgartner M, Mills PB, Clayton PT, Jakobs C, et al. Seizures and paroxysmal events: symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency. *Dev Med Child Neurol*. 2010;52:e133–e142. [PubMed] [Google Scholar]
51. Schubert J, Siekierska A, Langlois M, May P, Huneau C, et al. Mutations in *STX1B*, encoding a presynaptic protein, cause fever-associated epilepsy syndromes. *Nat Genet*. 2014;46:1327–1332. [PubMed] [Google Scholar]
52. Stamberger H, Nikanorova M, Willemsen M, Accorsi P, Angriman M, et al. *STXBPI* encephalopathy: a neurodevelopmental disorder including epilepsy. *Neurology*. 2016;86:954–962. [PubMed] [Google Scholar]
53. Sudarsanam A, Singh H, Wilcken B, Stormon M, Arbuckle S, et al. Cirrhosis associated with pyridoxal 5'-phosphate treatment of pyridoxamine 5'-phosphate oxidase deficiency. *JIMD Rep*. 2014;17:67–70. [PMC free article] [PubMed] [Google Scholar]
54. Syrbe S, Hedrich UBS, Riesch E, Djémié T, Müller S, et al. Hyperexcitability or electrical silencing: de novo loss- or gain-of-function mutations in *KCNA2* cause epileptic encephalopathy. *Nat Genet*. 2015;47:393–399. [PMC free article] [PubMed] [Google Scholar]
55. Talvik I, Møller RS, Vaher M, Vaher U, Larsen LHG, et al. Clinical phenotype of de novo *GNAO1* mutation: case report and review of literature. *Child Neurol Open*. 2015:1–7. [PMC free article] [PubMed] [Google Scholar]
56. Thomas RH, Berkovic SF. The hidden genetics of epilepsy-a clinically important new paradigm. *Nat Rev Neurol*. 2014;10:283–292. [PubMed] [Google Scholar]
57. Touma M, Joshi M, Connolly MC, Grant PE, Hansen AR, et al. Whole genome sequencing identifies *SCN2A* mutation in monozygotic twins with Ohtahara syndrome and unique neuropathologic findings. *Epilepsia*. 2013;54:e81–e85. [PMC free article] [PubMed] [Google Scholar]
58. Veeramah KR, O'Brien JE, Meisler MH, Cheng X, Dib-Hajj SD, et al. De novo pathogenic *SCN8A* mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP. *Am J Hum Genet*. 2012;90:502–510. [PMC free article] [PubMed] [Google Scholar]
59. Verbeek NE, van Kempen M, Gunning WB, Renier WO, Westland B, et al. Adults with a history of possible Dravet syndrome: an illustration of the importance of analysis of the *SCN1A* gene. *Epilepsia*. 2011;52:e23–e25. [PubMed] [Google Scholar]
60. Volkens L, Kahlig KM, Verbeek NE, Das JH, van Kempen MJ, et al. Nav 1.1 dysfunction in genetic epilepsy with febrile seizures-plus or Dravet syndrome. *Eur J Neurosci*. 2011;34:1268–1275. [PMC free article] [PubMed] [Google Scholar]

61. Wagnon JL, Meisler MH. Recurrent and non-recurrent mutations of *SCN8A* in epileptic encephalopathy. *Front Neurol*. 2015;6:104. [PMC free article] [PubMed] [Google Scholar]
62. Wang J, Gotway G, Pascual JM, Park JY. Diagnostic yield of clinical next-generation sequencing panels for epilepsy. *JAMA Neurol*. 2014;71:650–651. [PubMed] [Google Scholar]
63. Weber YG, Storch A, Wuttke TV, Brockmann K, Kempfle J, et al. *GLUT1* mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. *J Clin Invest*. 2008;118:2157–2168. [PMC free article] [PubMed] [Google Scholar]
64. Weckhuysen S, Holmgren P, Hendrickx R, Jansen A, Hasaerts D, et al. Reduction of seizure frequency after epilepsy surgery in a patient with STXBP1 encephalopathy and clinical description of six novel mutation carriers. *Epilepsia*. 2013;54:74–80. [PubMed] [Google Scholar]
65. Xiong HY, Alipanahi B, Lee LJ, Bretschneider H, Merico D, et al. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. *Science*. 2015;347:1254806. [PMC free article] [PubMed] [Google Scholar]
66. Yang Y, Muzny DM, Xia F, Niu Z, Person R, et al. Molecular findings among patients referred for clinical whole-exome sequencing. *JAMA*. 2014;312:1870–1879. [PMC free article] [PubMed] [Google Scholar]
67. Zara F, Specchio N, Striano P, Robbiano A, Gennaro E, et al. Genetic testing in benign familial epilepsies of the first year of life: clinical and diagnostic significance. *Epilepsia*. 2013;54:425–436. [PubMed] [Google Scholar]
68. Zorzi G, Castellotti B, Zibordi F, Gellera C, Nardocci N. Paroxysmal movement disorders in *GLUT1* deficiency syndrome. *Neurology*. 2008;71:146–148. [PubMed] [Google Scholar]